The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Cilta-cel vs standard of care in functional high-risk myeloma: findings from CARTITUDE-4
In the CARTITUDE-4 trial (NCT04181827), patients who had experienced an early relapse (within 18 months of receiving first-line therapy) were considered to have functional high-risk multiple myeloma (MM). In this video, Maria Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, comments on the study findings in this population. Dr Mateos highlights that the benefit on clinical outcomes conferred by ciltacabtagene autoleucel (cilta-cel) in the non-high-risk population was also seen in the patients with functional high-risk disease. These results suggest that cilta-cel could be the first choice treatment option at first relapse in this challenging patient population. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
